Evaluation of Efficacy and Safety Using oXiris Versus M100 Filter in Pneumonia-induced Acute Kidney Injury (AKI) Patients Requiring Continuous Renal Replacement Therapy (CRRT)
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of this study aimed to compare the efficacy of Oxiris (Baxter) and M100 filters on IL-6 as primary outcomes and other blood cell counts, blood biochemistry (serum urea, creatinine, potassium, sodium), inflammation indicators (CRP, PCT), as secondary outcomes and safety (28 days mortality as a primary outcome and coagulopathy, lifespan of filter, usage of vasopressor, clinical conditions (ventilator-free days, ICU and hospital- length of stay) as a secondary outcome), clinical conditions (ventilator-free days, ICU and hospital- length of stay), and mortality of patients with pneumonia-related AKI.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• All adult patients aged\>18 years old
• Diagnosis of septic shock
• Diagnosis of KDIGO stage 3 acute renal failure
Locations
Other Locations
Malaysia
Hospital Universiti Sains Malaysia (HUSM)
RECRUITING
Kubang Kerian
Contact Information
Primary
Marina Azidah Mat Zaid, MBBS
marinazaid@yahoo.com
0199870715
Time Frame
Start Date: 2024-05-30
Estimated Completion Date: 2026-05-01
Participants
Target number of participants: 60
Treatments
Experimental: oXiris filter
Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.~The 28-day mortality will be recorded following treatment.
Active_comparator: M100 filter
Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.~The 28-day mortality will be recorded following treatment.
Related Therapeutic Areas
Sponsors
Leads: Mohd Zulfakar Mazlan, MBBS